Takeda Pharmaceutical (TAK) Amortization (2017 - 2020)

Takeda Pharmaceutical's Amortization history runs 4 years deep, the most recent figure standing at $11.3 billion for Q1 2020.

• In Q1 2020, Amortization rose 1057.83% year-over-year to $11.3 billion; the TTM figure through Mar 2020 stood at $9.6 billion (changed N/A YoY), while the FY2020 annual figure was $11.3 billion, up 22059.72% from the prior year.
• Amortization was $11.3 billion for Q1 2020 at Takeda Pharmaceutical, up from -$1.2 billion in the prior quarter.
• In the past five years, Amortization ranged from a high of $11.3 billion in Q1 2020 to a low of -$1.2 billion in Q1 2019.
• Historically, Amortization has averaged $2.4 billion across 4 years, with a median of -$243.9 million in 2017.
• The sharpest annual moves came in 2018 and 2020: Amortization sank 400.85% in 2018, then jumped 1057.83% in 2020.
• A 4-year view of Amortization shows it stood at $242.9 million in 2017, then tumbled by 400.85% to -$730.8 million in 2018, then plunged by 61.43% to -$1.2 billion in 2019, then surged by 1057.83% to $11.3 billion in 2020.
• The last three Amortization figures came in at $11.3 billion (Q1 2020), -$1.2 billion (Q1 2019), and -$730.8 million (Q4 2018), per Business Quant data.